

AF and Venous Thromboembolism – Pathophysiology, Risk Assessment and CHADS₂-VASc score

Nasir Shariff^{1*}, Abdul Aleem², Mukesh Singh³, Yuan Z. Li⁴, Stacey J Smith⁴.

¹Department of Cardiovascular Medicine, Lehigh Valley Health Network, Pennsylvania, USA, ²Sri Siddhartha Medical College, Karnataka, India, ³Department of Cardiology, Chicago Medical School, North Chicago, Illinois, USA, ⁴Department of Medicine, Lehigh Valley Health Network, Pennsylvania, USA.

Abstract

Atrial fibrillation (AF) and venous thromboembolism (VTE) are the two most common medical conditions managed with anti-coagulation therapy. Not all the patients with decreased mobility or AF have a similar risk for thromboembolism. The risk factors for venous thromboembolism and thromboembolism associated with AF are described in various studies. Considering that the two conditions have similar pathophysiologic basis of clot formation, one could imply that the risk factors for the occurrence of thrombosis could be similar. The present review focuses on the similarities and differences in the clinical risk factors of VTE and AF related thromboembolism. We will also be discussing the role of CHADS₂-VASc scoring system in the risk assessment of VTE.

Introduction

In the mid eighteenth century, Virchow proposed a triad for the cause of venous thrombosis. This was constituted by stasis of blood, changes in the vessel wall and blood coagulability. Atrial fibrillation (AF), the most common sustained cardiac arrhythmia is associated with an increased risk of thromboembolism. In AF, all the changes occur in the atrium to fulfill Virchow's triad for thrombogenesis.¹ It is also noted that stroke patients suffering from AF have a higher incidence of venous thromboembolism (VTE).² Several factors have been studied and established as risk factors for developing VTE and thromboembolism in patients with AF. We will review the similarities and differences in these factors.

Epidemiology

An estimated 200,000 people in the United States

are diagnosed with VTE annually.³⁻⁷ This includes 106,000 patients with deep venous thrombosis (DVT) and 94,000 with pulmonary embolism (PE).³⁻⁷ The incidence of VTE occurring for the first time in about 100 per 100,000 people.⁶ VTE contributes to about 300,000 to 600,000 hospitalizations and 100,000 deaths annually. Death occurs in about 6% of patients with DVT and 12% of PE cases within a month of diagnosis.⁶ In the International Cooperative Pulmonary Embolism Registry (ICOPER), all-cause mortality rate at 3 months, associated with PE was 17%.⁸ In the Worcester, Massachusetts metropolitan area study, patients with PE had mortality rate of 11.1%.⁹

AF is the commonest sustained cardiac arrhythmia, which is associated with significant risk of morbidity and mortality resulting from thromboembolism.¹⁰ Approximately 2.2 million Americans suffer from AF.¹¹⁻¹² By 2050, an estimated 16 million Americans are predicted to have AF.¹³ On

Corresponding Address : Dr.Nasir Shariff, MD, Lehigh Valley Hospital and Health Network, Allentown, PA 18103.

screening of patients with ischemic stroke, AF is recognized in 6.7% of patients on routine electrocardiogram, 10.6% on 24 hour Holter and 15.6% with 7 day event monitor.¹⁴ While the stroke risk is increased by 5 folds by AF, this risk is not homogeneous as it is altered by other stroke risk factors.¹⁰

Pathophysiology

Hemostasis is primarily a protective mechanism of reducing bleeding after vascular injury. In situations of endothelial dysfunction, stasis or hypercoagulability, there is increased activation of this protective mechanism resulting in thrombosis. Arterial and venous thromboses are two pathophysiologically distinct entities with different clinical presentations and management strategies. Arterial thrombosis generally develops as a result of underlying vascular abnormalities, typically atherosclerotic disease and is largely a phenomenon of platelet activation. Unlike arterial thrombosis, venous thrombosis occurs in regions of sluggish blood flow and is largely a matter of activation of the clotting system.¹⁵ The venous clots are relatively larger in size compared to arterial clots and are composed predominantly of fibrin enmeshed with cellular components including red blood cells. Activation of the coagulation system is the primary cause of venous thrombosis and precedes platelet activation and aggregation.¹⁶ Surgery or trauma may cause direct injury to the vessels resulting in exposure of the subendothelial tissue factor (TF). This however, is not common in non-surgical patients with VTE. Venous stasis promotes thrombus formation by not flushing out the activated coagulation factors from endothelial dysfunction. Circulating TF-bearing microparticles are also suggested to play an important role in VTE. These particles attach to activated endothelial cells and transfer TF to them initiating coagulation reactions and clot formation.¹⁷⁻¹⁸ This is different from thrombus formation in the arterial system. The TF-bearing micro-particles may also contribute to the hypercoagulable state associated with disease conditions with an increased risk of DVT.¹⁷⁻¹⁹ In patients with AF, there is abnormal stasis of blood in the atrium with endothelial dysfunction, and hypercoagulable states resulting in thrombus formation.^{1,20} Systemic fibrinogen and fibrin D-dimer levels are elevated in patients with persistent and paroxysmal AF which increases the

procoagulant state.¹ Both von Willebrand factor and TF are also over expressed in the atrial endothelium of patients with AF who have a history of thromboembolism.¹ AF seems to fulfill the Virchow's triad for thrombogenesis, and the thrombus formed has a 'venous-type clot'. These findings are suggestive of similar pathophysiologic basis for clot formation for VTE and AF, which may imply similar risk factors for the occurrence of thrombosis. This could also explain for the success of anticoagulants and not antiplatelets in the prevention of VTE and AF related strokes.²¹⁻²³

Risk Factors for VTE and AF Thromboembolism

Systematic reviews of epidemiologic cohorts and clinical trials have identified various risk factors associated with AF and their impact on stroke.²⁴⁻²⁵ The risk factors and their adjusted relative risk (RR) as described by the Stroke in AF Working Group are: previous stroke/transient ischemic attack (TIA) (RR 2.5), age (RR 1.5/decade), hypertension (RR 2.0), diabetes (RR 1.8) and female gender (RR 1.6).²⁴⁻²⁵ Congestive heart failure (CHF) history was not associated with stroke risk in this study, although moderate systolic dysfunction was still an independent predictor. In a systemic review by the National Institute of Health and Clinical Evidence (NICE), history of stroke or TIA, advanced age, hypertension and structural heart disease were predictors of stroke.²⁵ Diabetes mellitus and gender were not significant factors to predict stroke risk in this review. The CHADS₂ score was derived by adding the AF investigators and Stroke Prevention in AF (SPAF) -1 trials.²⁶ The factors included were CHF, hypertension, age > 75 years, diabetes mellitus, and prior stroke/TIA. This scoring was simple and was validated in assessing the risk of thromboembolic stroke in patients with AF. However, it could not differentiate very low risk group from low risk and intermediate risk groups.²⁶ To further refine and define the risk of stroke in AF patients, the European Society of Cardiology came up with the CHADS-VASc score to complement the CHADS₂ scheme.²⁷ In this the major risk factors were age > 75 years and previous stroke/TIA (with allocated two points); the non-major risk factors were CHF, hypertension, diabetes mellitus, age between 65 years and

75 years, vascular disease and female gender (with allocated one point for each) (see Table 1).²⁸ The CHADS-VASc score has also been well validated and is efficient in identifying patients at high and moderate risk of thromboembolic events.²⁸⁻²⁹ Absence of the risk factors as defined by the CHADS-VASc score identifies patient who are at very low risk of thromboembolism or stroke.³⁰ In low risk

Table 1 Factors and adjusted thromboembolic stroke risks in patients with atrial fibrillation (CHADS-VASc scoring)

Major risk factors (assigned 2 points)	
Aged \geq 75 years	
Stroke/Transient ischemic stroke	
Minor risk factors (assigned 1 point)	
Congestive heart failure	
Hypertension	
Diabetes mellitus	
Vascular disease (prior myocardial infarct, peripheral arterial disease)	
Aged 65–74 years	
Sex category (female gender)	
Score	Adjusted stroke rate (% per year)
0	0%
1	1.3%
2	2.2%
3	3.2%
4	4.0%
5	6.7%
6	9.8%
7	9.6%
8	6.7%
9	15.2%

Adapted from European Heart Rhythm Association Guidelines [27] and Lip GY, et al.²⁸

patients (CHADS-VASc score = 0), the rate of thromboembolism per 100 person-years was 1.67 [95% confidence interval (CI) 1.47–1.89].³⁰ Presence of any of the minor risk factors significantly increased the risk of stroke (absolute risk 2.01; 95% CI 1.70–2.36). The negative predictive value (i.e. the percent categorized as not being at higher risk, actually being free from thromboembolism) for CHADS-VASc was 99.5% suggesting that other clinical or laboratory factors may not have significant contribution to thromboembolic risk.

VTE is a multifactorial disease with 2 or more risk factors being present at the same time.³¹ An

overview of the risk factors for VTE is provided in Table 2.³² Genetic risk factors predisposing for VTE include deficiencies of antithrombin, protein C, protein S, and the factor V Leiden (FVL) mutation and prothrombin 20210A gene variant.³³ Genetic factors including variations in antithrombin, protein C, or protein S deficiencies are associated with approximately 5 to 10 fold, 4 to 6 fold and 1 to 10 fold increased risk of VTE respectively.³⁴⁻³⁵ Prothrombin G20210A variant and FVL mutation are associated with 3 and 7 fold increased risk of VTE respectively.³⁶⁻³⁷ But for these genetic risk factors, there are several acquired clinical risk factors which increase the risk for VTE. The clinical risk factors include triggering factors and demographic and chronic medical conditions. The

Table 2 Risk factors for venous thrombosis and pulmonary embolism

Primary (unprovoked)

Old age (>65 years)
Long-haul travel
Thrombophilia (factor V Leiden or prothrombin gene mutation)
Obesity
Cigarette smoking
Hypertension
Metabolic syndrome

Secondary (provoked)

Immobilization
Postoperative
Trauma
Oral contraceptives, pregnancy
Cancer
Acute medical illness (e.g. Pneumonia, congestive heart failure)

Adapted from Goldhaber SZ, et al.³²

triggering factors include immobilization, plaster casts, surgery, and trauma. The demographic and medical conditions include cancer, obesity, increasing age, hormone replacement therapy and pregnancy.³⁸ These acquired factors cause either stasis or hypercoagulability predisposing to VTE. Hospitalization is a risk factor for VTE considering that these patients are exposed to more than one acquired risk factor including immobility, cancer, surgery, CHF, infections and chronic kidney disease.³⁹

Relevant Risk Factors for Similarities and Differences

Similar to thrombosis in patients with AF, a com-

bination of various risk factors increases the risk for VTE episodes. Genetic risk factors (deficiency of protein C and S, and FVL mutation), and temporary triggering risk factors (trauma, surgery, pregnancy) that predispose to the development of VTE have not been studied extensively in patients with AF. Hence these factors will not be reviewed. In our discussion we will be describing the studies which have established the role of the different risk factors (i.e. CHADS-VASc score) in assessing risk of thromboembolism in patients with AF. We will also discuss the implication of these factors in assessing VTE risk.

a. Age

Levels of prothrombin activation fragment F1.2, an index of thrombin generation, increase with age in the general population⁴⁰⁻⁴² suggesting an age-related prothrombotic diathesis. In patients with AF, aging is associated with left atrial (LA) enlargement, reduced left atrial appendage (LAA) flow velocity, and spontaneous echo contrast (SEC), all of which predispose to LA thrombus formation.⁴³⁻⁴⁵ The implication of aging on risk of stroke in patients with AF has been evaluated in 17 studies.⁴⁶ Twelve studies found an independent effect of age on stroke risk while five studies failed to find such an association.⁴⁶ In the analysis of pooled data from five randomized controlled trials, the annual risk of stroke increased from 15% to 20% in patients aged <65 years and >65 years with no other risk factors and from 17% to 27% in patients with one or more risk factors for stroke.⁴⁷ In this study the overall relative risk of stroke associated with every decade of life was 1.4 (95% CI 1.1-1.8). In the Framingham study, age 65 years and older was associated with a 3-fold increase in risk of stroke.⁴⁸

VTE has an incidence of 1 to 2 cases per 1000 person-years, with age-dependent incidence ranging from 1 in 100000 in children to 1 in 100 in older individuals.⁴⁹⁻⁵¹ VTE rises exponentially from <5 cases per 100000 persons in younger than 15 years age to about 500 cases (0.5%) per 100000 persons at age 80 years.⁶ The incidence of VTE increased significantly with age in a population based study with the noted incidence of about 100 per 100000 in people aged 50 years and more than 450 per 100000 in people aged 75 years.⁵² Thus, advanced age is a risk factor for thromboembolism associated with

AF as well as for development of VTE.

b. Sex (female gender)

Women face several unique situations during their lifetime, such as pregnancy, use of oral contraceptives and hormone replacement therapies, all of which increase their risk of thromboembolism. In AF, female gender has been observed to be a significant risk factor for thromboembolic stroke in some studies⁵³⁻⁵⁷ but not in others.⁵⁸⁻⁶² In the SPAF trial, 2012 participants given aspirin were evaluated, female gender was associated with significantly higher risk of stroke with a RR of 1.6.⁵³ Similar to this trial, the Framingham study and the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study noted a significantly higher incidence of stroke in women with AF with the noted RR of 1.7 and 1.6 respectively.^{55,63} In the AFASAK trial, female gender was not associated with occurrence of stroke. Of note, there was no association of age or left atrial size with increased incidence of stroke in this study.⁵⁹ Similar to this study, Aronow et al, did not find any association of gender with risk of thromboembolic stroke in elderly patients with chronic AF.⁶¹

In a Norwegian study, the incidence of first VTE events was 1.43 per 1000 person-years, with a noted slightly higher events in women than in men.⁵⁰ Contradictory to this finding, in a community-based study, incidence was higher for men than for women (1.14 per 1000 patient-years vs. 1.05 per 1000 patient-years).⁶⁴ In the Olmsted county study, the age-adjusted rates of VTE was significantly higher in males than females (130 vs. 110 per 100000 patient-years).⁵² In this study it was noted that the incidence of VTE in women younger than 55 years, was higher than men. This finding may be related to the differential exposure to clinical risk factors in this specific population of women (pregnancy, postpartum state, or oral contraceptive use). In a meta-analysis of 15 studies (nine randomized controlled and six prospective observational), the estimate of the RR of recurrent VTE for men was significantly higher compared to women (RR 1.6, 95% CI 1.2-2.0).⁶⁵ In conclusion, women younger than 55 years age are at a higher risk of VTE, but with aging the risk of VTE is similar or higher in men.

c. Hypertension

Hypertension is a common risk factor for arterial thrombosis and also AF. Hypertension in patients with AF is associated with reduced left atrial appendage (LAA) flow velocity, spontaneous echo-contrast (SEC), and thrombus formation.^{43,44,66} Ventricular diastolic dysfunction might underlie the effect of hypertension on left atrial (LA) dynamics, but this relationship is still speculative.⁶⁷⁻⁶⁸ Hypertension is an important predictor of stroke in patients with AF,^{48,53-54,58,61,69-70} especially in those with systolic blood pressure greater than 160 mm Hg.^{53-54,56} During a 2.0 year follow-up of patients with non-valvular AF, history of hypertension was associated with significantly higher risk of stroke with a RR of 2.0.⁵³ In a systematic review of risk factors for stroke in patients with AF, hypertension was associated with increased risk (RR 2.0, 95% CI 1.6-2.5).²⁴

In a study involving the population from the Atherosclerosis Risk In Communities (ARIC) and Cardiovascular Health Study (CHS) to assess the association of established risk factors of arterial thromboembolism, hypertension was not associated with VTE.⁷¹ The relative risk for VTE in patients with history of hypertension was 1.20 (95% CI 0.90-1.60) which was comparable to patients with normal blood pressures (RR 1.21 (95% CI 0.99-1.47)). There was no difference when groups with systolic blood pressure less than 114 mmHg were compared with patients with systolic blood pressure between 114 and 130 mmHg and those with systolic blood pressure of more than 140 mmHg. In another study of patients with antiphospholipid syndrome, presence of hypertension increased the incidence of arterial thromboembolism but not VTE.⁷²

d. Diabetes Mellitus

Diabetes mellitus has been associated with enhanced coagulation and reduced fibrinolytic potential which may contribute to thrombosis.⁷³ In the meta-analysis of independent predictors of stroke in non-anticoagulated patient with non-valvular AF by the Stroke Risk in AF Working Group, seven studies were assessed.²⁴ Diabetes was present in 15% of the study cohorts and was an independent risk factor for stroke. (RR 1.7, 95%

CI 1.4-2.0).²⁴ Studies indicate that the reduction in stroke among warfarin-treated patients with diabetes was below average.⁷⁴⁻⁷⁵

In a study of assessing the association of traditional cardiovascular risk factors on occurrence of VTE, diabetes and obesity were each associated with significant increase in events even in age, race and sex adjusted models.⁷¹ In this study the incidence of VTE increased from 0.83 events per 1000 person-years in non-diabetics to 2.12 events per 1000 person-years among diabetics (RR 1.70, 95% CI: 1.20-2.40).⁷¹ On adjusting for body mass index (BMI), diabetes still persisted to be significantly associated with VTE though the risk for events was attenuated (HR 1.46, 95% CI 1.03-2.05). Diabetic patients also had higher secondary events of VTE as compared to patients with idiopathic VTE (HR 1.62 vs. 1.27 respectively).

e. Congestive Heart Failure

CHF is a prothrombotic state resulting from impaired blood flow due to poor myocardial contraction. This is compounded by endothelial dysfunction, abundance of adhesion molecules and an imbalance of procoagulants and anticoagulants.⁷⁶ Patients with CHF have abnormally elevated von Willebrand factor levels, soluble thrombomodulin (indexes of endothelial damage/dysfunction) and soluble E-selectin (an index of endothelial activation).⁸ It is well established that AF and CHF are inter-related in a varieties of ways with each predisposing to the occurrence of other. In regards to the risk of stroke in patients with both AF and CHF, there are different studies noting variable association. In the SPAF trial, recent (within 3 months) history of CHF was independently associated with a substantial risk for thromboembolism (greater than 7% per year).⁶⁹ In contrast to this study, the Embolism in Left Atrial Thrombi (ELAT) study did not find an association of CHF with occurrence of stroke. However, in this study there was significant relation of CHF with all cause mortality.⁷⁷ In the Stroke in AF Working Group assessment, CHF was not significantly associated with stroke. The presence of moderate systolic left ventricular dysfunction was still an independent marker.²⁴ In the National Institute for Health and Clinical Evidence (NICE) review, structural heart disease was independently associated with stroke occurrence.²⁵

Stasis of blood in the lower extremities in patients with CHF activates coagulation system, leading to fibrin formation which results in thrombus formation in the extremities. The reported incidence of DVT in patients with CHF ranges from 1% to 59% and that for PE from 1% to 39%.^{3,78-81} In a review of the US National Hospital Discharge Survey, the incidence of PE and DVT were significantly higher in patients with diagnosis of CHF than those without CHF. The noted relative risks of 2.15 and 1.21 respectively.⁸² In a study addressing the out-patient risk, CHF was an independent risk factor for VTE with an adjusted OR of 2.6 (95% CI, 1.4-4.7).⁸³

f. Stroke

Stroke is a consequence of a prothrombotic state resulting in occlusion of the cerebral arteries. Stroke is the most feared complication of AF. History of stroke/TIA in turn increases events of thromboembolism associated with AF and hence secondary event of strokes. Several studies have found a previous history of stroke or TIA to be a significant independent risk factor for secondary stroke.^{53-55,62,69} AF increases the risk of stroke by five-fold, and the use of anticoagulation reduces this risk by two-thirds whilst antiplatelet therapy reduces stroke by one-fifth.⁸⁴⁻⁸⁵ In a systematic evaluation of risks, prior stroke/TIA had the higher risk association for stroke occurrence in patients with AF (RR 2.5, 95% CI: 1.8-3.5).²⁴ Stroke patients are at high risk for VTE due to immobility caused by stroke.

Patients with stroke have several related risk factors including immobility, hypertension, diabetes, hospitalization which increase the incidence of VTE. The incidence of DVT within the first 2 weeks after stroke ranges from 10% to 75%, depending on the diagnostic method and timing of evaluation.⁸⁶ In patients with acute hemiplegic stroke, the incidence of DVT is approximately 50% within 2 weeks in the absence of prophylaxis.⁸⁷ In another study, among patients who were not on any prophylactic precautions, the incidence of DVT was found to be 53% in the paralyzed leg and 5% in the non-paralyzed leg.⁸⁸ In a MRI based direct thrombus imaging study, of the 102 unselected patients with acute ischemic stroke, the prevalence of all VTE, DVT, and PE after 21 days were 40%, 18%, and 12% respectively.⁸⁹ In this study, non-ambulatory status of patients around the time of admission to the hospital was found to predict higher

risk of VTE. In the International Stroke Trial (IST), the incidence of PE in patients with stroke was 0.8% at 2 weeks in patients not receiving heparin prophylaxis and 0.5% in patients receiving heparin prophylaxis.⁹⁰ This relatively lower incidence of PE reported in the IST study could be due to under-reporting or to early mobilization of patients not described in the study.

g. Vascular disease

Patients with peripheral vascular disease have other risk factors for the thromboembolism which include hypertension, diabetes, myocardial infarction and structural heart disease. These factors have been associated with VTE and also thromboembolism with AF. Peripheral arterial disease confers a poor prognosis in patients with AF. They have high rates of mortality, cardiovascular events, and stroke.⁹¹⁻⁹³ Lin et al⁹⁴ in their nationwide cohort study found that peripheral artery disease was an independent predictor of stroke among non-anticoagulated AF patients, with odds ratio of 1.8 (95% CI, 1.2-2.8). Vascular disease, including peripheral artery disease, was also a risk factor of subsequent stroke in AF patients age <65 years in the Loire Valley Atrial Fibrillation Project,⁹⁵ and peripheral artery disease was an independent predictor of stroke and death in the Danish Diet, Cancer, and Health Study.⁹⁶ Rasmussen et al found an incidence rate of stroke at 1-year follow-up of 10.9 per 100 person-years in patients with new-onset AF and peripheral artery disease, vs. a rate of 4.6 in new-onset AF patients without vascular disease.⁹⁶ In a Danish nationwide cohort study, the presence of vascular disease also increased the risk of thromboembolism significantly at 5 and 10 years of follow-up, with hazard ratios (HRs) of 2.04 and 2.22, respectively.³⁰

In a small observation study of 176 patients, there was noted significantly higher incidence of DVT in patients admitted for arteriography, angioplasty or arterial reconstruction surgeries when compared to control patients without peripheral vascular disease.⁹⁷ In review of a large US health-care claims database of hospitalized medically ill patients of age > 40 years age, a diagnosis of peripheral arterial disease at index admission was significantly associated with incidence of venous thromboembolism within 90 days of hospital admission (HR 1.68, 95% CI 1.28-2.21).⁹⁸

CHAD-VASc Risk Factors and VTE

Of the CHAD-VaSc risk factors, five appear to be associated with the occurrence of VTE; these include age, CHF, diabetes, stroke and peripheral vascular disease. Patients aged over 75 years have a 5 fold increased risk when compared to patients aged <50 years. CHF also increases the incidence of VTE. The OR of DVT and PE in patients with CHF is 2.15 and 1.21 respectively. Diabetes has been noted to increase the incidence of VTE by 2 fold. Similarly, stroke significantly increases the risk of VTE. The noted incidence of DVT in patients with stroke ranges from 10% to 75%. After an index hospital admission for peripheral arterial disease, higher incidence of DVT was noted within 90 days with HR of 1.68 for the occurrence of VTE. As far as gender is concerned, women younger than 55 years of age are at a higher risk of VTE, but after 55 years, the risk of VTE is similar or higher in men. Hypertension does not seem to predispose to the development of VTE.

Conclusions

AF and VTE are two common medical conditions associated with significant morbidity and mortality. They share a similar pathophysiology for the development of thrombus and management with anticoagulants. The CHADS-VASc risk factors have been well validated in assessing the risk of thromboembolism associated with AF. Considering the similarities of AF and VTE, these factors may have a role in risk assessment of VTE. Though risk factors including age, CHF, diabetes, stroke and peripheral vascular disease predispose to the development of both conditions; factors including hypertension and sex have differential association with the two conditions. The studies in general have not been exclusively directed to assess the CHADS-VASc score risk factors on incidence of VTE and hence further studies are needed to specifically delineate these factors and the use of CHADS-VASc score for risk assessment of VTE.

Disclosures

No disclosures relevant to this article were made by the authors.

References

1. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. *Lancet*. 2009;373:155-66.
2. Noel P, Gregoire F, Capon A, Leheret P. Atrial fibrillation as a risk factor for deep venous thrombosis and pulmonary emboli in stroke patients. *Stroke*. 1991;22:760-2.
3. Anderson FA, Jr., Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. *Arch Intern Med*. 1991;151:933-8.
4. Dalen JE, Alpert JS. Natural history of pulmonary embolism. *Prog Cardiovasc Dis*. 1975;17:259-70.
5. Clagett GP, Anderson FA, Jr., Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism. *Chest*. 1995;108:312S-34S.
6. White RH. The epidemiology of venous thromboembolism. *Circulation*. 2003;107:14-8.
7. Garg K, Keith RL, Byers T, Kelly K, Kerzner AL, Lynch DA, et al. Randomized controlled trial with low-dose spiral CT for lung cancer screening: feasibility study and preliminary results. *Radiology*. 2002;225:506-10.
8. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). *Lancet*. 1999;353:1386-9.
9. Spencer FA, Goldberg RJ, Lessard D, Reed G, Emery C, Gore JM, et al. Factors associated with adverse outcomes in outpatients presenting with pulmonary embolism: the Worcester Venous Thromboembolism Study. *Circ Cardiovasc Qual Outcomes*. 2010;3:390-4.
10. Lip GY, Lim HS. Atrial fibrillation and stroke prevention. *Lancet Neurol*. 2007;6:981-93.
11. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, et al. Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation*. 2007;115:e69-171.
12. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. *Arch Intern Med*. 1995;155:469-73.
13. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. *Circulation*. 2006;114:119-25.
14. Jabaudon D, Sztajzel J, Sievert K, Landis T, Sztajzel R. Usefulness of ambulatory 7-day ECG monitoring for the detection of atrial fibrillation and flutter after acute stroke and transient ischemic attack. *Stroke*. 2004;35:1647-51.
15. Kroegel C, Reissig A. Principle mechanisms underlying venous thromboembolism: epidemiology, risk factors, pathophysiology and pathogenesis. *Respiration*. 2003;70:7-30.
16. Lopez JA, Kearon C, Lee AY. Deep venous thrombosis. *Hematology Am Soc Hematol Educ Program*. 2004:439-56.
17. Furie B, Furie BC. Mechanisms of thrombus formation. *N*

- Engl J Med. 2008;359:938-49.
18. Esmon CT. Crosstalk between inflammation and thrombosis. *Maturitas*. 2008;61:122-31.
19. Esmon CT. Basic mechanisms and pathogenesis of venous thrombosis. *Blood Rev*. 2009;23:225-9.
20. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. *Eur Heart J*. 2001;22:1852-923.
21. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*. 2008;133:381S-453S.
22. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*. 2004;126:429S-56S.
23. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*. 2004;126:401S-28S.
24. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. *Neurology*. 2007;69:546-54.
25. Hughes M, Lip GY. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. *Thromb Haemost*. 2008;99:295-304.
26. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. *JAMA*. 2001;285:2864-70.
27. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). *Eur Heart J*. 2010;31:2369-429.
28. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest*. 2010;137:263-72.
29. Van Staa TP, Setakis E, Di Tanna GL, Lane DA, Lip GY. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. *J Thromb Haemost*. 2011;9:39-48.
30. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. *BMJ*. 2011;342:d124.
31. Rosendaal FR. Venous thrombosis: a multicausal disease. *Lancet*. 1999;353:1167-73.
32. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. *Lancet*. 2012;379:1835-46.
33. Cushman M. Epidemiology and risk factors for venous thrombosis. *Semin Hematol*. 2007;44:62-9.
34. Koster T, Rosendaal FR, Briet E, van der Meer FJ, Colly LP, Trienekens PH, et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). *Blood*. 1995;85:2756-61.
35. Middeldorp S, van Hylckama Vlieg A. Does thrombophilia testing help in the clinical management of patients? *Br J Haematol*. 2008;143:321-35.
36. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. *Nature*. 1994;369:64-7.
37. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. *Blood*. 1996;88:3698-703.
38. Smalberg JH, Kruip MJ, Janssen HL, Rijken DC, Leebeek FW, de Maat MP. Hypercoagulability and hypofibrinolysis and risk of deep vein thrombosis and splanchnic vein thrombosis: similarities and differences. *Arterioscler Thromb Vasc Biol*. 2011;31:485-93.
39. Heit JA, O'Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. *Arch Intern Med*. 2002;162:1245-8.
40. Cushman M, Psaty BM, Macy E, Bovill EG, Cornell ES, Kuller LH, et al. Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease. *Arterioscler Thromb Vasc Biol*. 1996;16:1163-9.
41. Hursting MJ, Stead AG, Crout FV, Horvath BZ, Moore BM. Effects of age, race, sex, and smoking on prothrombin fragment 1.2 in a healthy population. *Clin Chem*. 1993;39:683-6.
42. Lowe GD, Rumley A, Woodward M, Morrison CE, Philippou H, Lane DA, et al. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. *Br J Haematol*. 1997;97:775-84.
43. Goldman ME, Pearce LA, Hart RG, Zabalgoitia M, Asinger RW, Safford R, et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). *J Am Soc Echocardiogr*. 1999;12:1080-7.
44. Asinger RW, Koehler J, Pearce LA, Zabalgoitia M, Blackshear JL, Fenster PE, et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: II. Dense spontaneous echocardiographic contrast (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). *J Am Soc Echocardiogr*. 1999;12:1088-96.
45. Dittrich HC, Pearce LA, Asinger RW, McBride R, Webel R, Zabalgoitia M, et al. Left atrial diameter in nonvalvular atrial fibrillation: An echocardiographic study. *Stroke Prevention in Atrial*

Fibrillation Investigators. *Am Heart J*. 1999;137:494-9.

46. Marinigh R, Lip GY, Fiotti N, Giansante C, Lane DA. Age as a risk factor for stroke in atrial fibrillation patients implications for thromboprophylaxis: Implications for thromboprophylaxis. *J Am Coll Cardiol*. 2010;56:827-37.

47. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. *Arch Intern Med*. 1994;154:1449-57.

48. Moulton AW, Singer DE, Haas JS. Risk factors for stroke in patients with nonrheumatic atrial fibrillation: a case-control study. *Am J Med*. 1991;91:156-61.

49. Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. *J Thromb Haemost*. 2005;3:1611-7.

50. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. *J Thromb Haemost*. 2007;5:692-9.

51. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. *Thromb Haemost*. 2000;83:657-60.

52. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ, 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. *Arch Intern Med*. 1998;158:585-93.

53. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. *Stroke*. 1999;30:1223-9.

54. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. *J Am Coll Cardiol*. 2000;35:183-7.

55. Wang TJ, Massaro JM, Levy D, Vasani RS, Wolf PA, D'Agostino RB, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. *JAMA*. 2003;290:1049-56.

56. van Latum JC, Koudstaal PJ, Venables GS, van Gijn J, Kappelle LJ, Algra A. Predictors of major vascular events in patients with a transient ischemic attack or minor ischemic stroke and with nonrheumatic atrial fibrillation. European Atrial Fibrillation Trial (EAFT) Study Group. *Stroke*. 1995;26:801-6.

57. Cabin HS, Clubb KS, Hall C, Perlmutter RA, Feinstein AR. Risk for systemic embolization of atrial fibrillation without mitral stenosis. *Am J Cardiol*. 1990;65:1112-6.

58. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. *JAMA*. 1998;279:1273-7.

59. Petersen P, Kastrup J, Helweg-Larsen S, Boysen G, Godtfredsen J. Risk factors for thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. *Arch Intern Med*. 1990;150:819-21.

60. Nakagami H, Yamamoto K, Ikeda U, Mitsuhashi T, Goto T, Shimada K. Mitral regurgitation reduces the risk of stroke in patients with nonrheumatic atrial fibrillation. *Am Heart J*. 1998;136:528-32.

61. Aronow WS, Gutstein H, Hsieh FY. Risk factors for thromboembolic stroke in elderly patients with chronic atrial fibrillation. *Am J Cardiol*. 1989;63:366-7.

62. Aronow WS, Ahn C, Kronzon I, Gutstein H. Risk factors for new thromboembolic stroke in patients > or = 62 years of age with chronic atrial fibrillation. *Am J Cardiol*. 1998;82:119-21.

63. Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. *Circulation*. 2005;112:1687-91.

64. Heit JA. The epidemiology of venous thromboembolism in the community. *Arterioscler Thromb Vasc Biol*. 2008;28:370-2.

65. McRae S, Tran H, Schulman S, Ginsberg J, Kearon C. Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. *Lancet*. 2006;368:371-8.

66. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. *J Am Coll Cardiol*. 1998;31:1622-6.

67. Dreslinski GR, Frohlich ED, Dunn FG, Messerli FH, Suarez DH, Reisin E. Echocardiographic diastolic ventricular abnormality in hypertensive heart disease: atrial emptying index. *Am J Cardiol*. 1981;47:1087-90.

68. Frohlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, Dzau V, et al. The heart in hypertension. *N Engl J Med*. 1992;327:998-1008.

69. Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. *Ann Intern Med*. 1992;116:1-5.

70. Seidl K, Hauer B, Schwick NG, Zellner D, Zahn R, Senges J. Risk of thromboembolic events in patients with atrial flutter. *Am J Cardiol*. 1998;82:580-3.

71. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. *Arch Intern Med*. 2002;162:1182-9.

72. Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. *Rheumatology (Oxford)*. 2002;41:924-9.

73. MacCallum PK, Meade TW. Haemostatic function, arterial disease and the prevention of arterial thrombosis. *Baillieres Best Pract Res Clin Haematol*. 1999;12:577-99.

74. Go AS, Reed GL, Hylek EM, Phillips KA, Liu L, Henault LE, et al. Factor V Leiden and risk of ischemic stroke in nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *J Thromb Thrombolysis*. 2003;15:41-6.

75. van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly

- S, Petersen P, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. *JAMA*. 2002;288:2441-8.
76. Chong AY, Lip GY. Viewpoint: the prothrombotic state in heart failure: a maladaptive inflammatory response? *Eur J Heart Fail*. 2007;9:124-8.
77. Stollberger C, Chnupa P, Abzieher C, Langer T, Finsterer J, Klem I, et al. Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the embolism in left atrial thrombi (ELAT) study. *Clin Cardiol*. 2004;27:40-6.
78. Dries DL, Rosenberg YD, Waclawiw MA, Domanski MJ. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. *J Am Coll Cardiol*. 1997;29:1074-80.
79. Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN. Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. *Circulation*. 1993;87:VI94-101.
80. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. *Arch Intern Med*. 2000;160:3415-20.
81. Cogo A, Bernardi E, Prandoni P, Girolami B, Noventa F, Simioni P, et al. Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. *Arch Intern Med*. 1994;154:164-8.
82. Beemath A, Stein PD, Skaf E, Al Sibae MR, Alesh I. Risk of venous thromboembolism in patients hospitalized with heart failure. *Am J Cardiol*. 2006;98:793-5.
83. Howell MD, Geraci JM, Knowlton AA. Congestive heart failure and outpatient risk of venous thromboembolism: a retrospective, case-control study. *J Clin Epidemiol*. 2001;54:810-6.
84. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Ann Intern Med*. 2007;146:857-67.
85. Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. *Thromb Res*. 2006;118:321-33.
86. Bembenek J, Karlinski M, Kobayashi A, Czlonkowska A. Early stroke-related deep venous thrombosis: risk factors and influence on outcome. *J Thromb Thrombolysis*. 2011;32:96-102.
87. Brandstater ME, Roth EJ, Siebens HC. Venous thromboembolism in stroke: literature review and implications for clinical practice. *Arch Phys Med Rehabil*. 1992;73:S379-91.
88. Warlow C, Ogston D, Douglas AS. Deep venous thrombosis of the legs after strokes. Part I--incidence and predisposing factors. *Br Med J*. 1976;1:1178-81.
89. Kelly J, Rudd A, Lewis RR, Coshall C, Moody A, Hunt BJ. Venous thromboembolism after acute ischemic stroke: a prospective study using magnetic resonance direct thrombus imaging. *Stroke*. 2004;35:2320-5.
90. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. *Lancet*. 1997;349:1569-81.
91. Conway DS, Lip GY. Comparison of outcomes of patients with symptomatic peripheral artery disease with and without atrial fibrillation (the West Birmingham Atrial Fibrillation Project). *Am J Cardiol*. 2004;93:1422-5, A10.
92. Goto S, Bhatt DL, Rother J, Alberts M, Hill MD, Ikeda Y, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. *Am Heart J*. 2008;156:855-63, 63 e2.
93. Frost L, Engholm G, Johnsen S, Moller H, Husted S. Incident stroke after discharge from the hospital with a diagnosis of atrial fibrillation. *Am J Med*. 2000;108:36-40.
94. Lin LY, Lee CH, Yu CC, Tsai CT, Lai LP, Hwang JJ, et al. Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation--a nation wide database analysis. *Atherosclerosis*. 2011;217:292-5.
95. Olesen JB, Fauchier L, Lane DA, Taillandier S, Lip GY. Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. *Chest*. 2012;141:147-53.
96. Rasmussen LH, Larsen TB, Due KM, Tjonneland A, Overvad K, Lip GY. Impact of vascular disease in predicting stroke and death in patients with atrial fibrillation: the Danish Diet, Cancer and Health cohort study. *J Thromb Haemost*. 2011;9:1301-7.
97. Libertiny G, Hands L. Deep venous thrombosis in peripheral vascular disease. *Br J Surg*. 1999;86:907-10.
98. Edelsberg J, Hagiwara M, Taneja C, Oster G. Risk of venous thromboembolism among hospitalized medically ill patients. *Am J Health Syst Pharm*. 2006;63:S16-22.